Image source: Shutterstock

Highlights

  • Pro Medicus partners with UCSF for AI-powered medical imaging research.
  • Shares of Pro Medicus rise to $213.50 on the back of the deal.
  • The collaboration aims to enhance AI development using Visage technology.

Pro Medicus Ltd (ASX: PME) shares saw a slight increase to AU$213.50 on Tuesday following the announcement of a multi-year research collaboration with the University of California, San Francisco (UCSF). The health imaging technology company entered into the agreement to advance artificial intelligence (AI) research in medical imaging using its Visage platform.

The collaboration allows UCSF to leverage Pro Medicus' Visage AI Accelerator. This platform integrates engineering, clinical research, and real-world application, enabling researchers to securely gather and analyze medical imaging data. It also facilitates the testing of AI algorithms and helps bring successful projects directly into clinical workflows.

Malte Westerhoff, the global CTO of Pro Medicus' Visage Imaging subsidiary, emphasised the unique capabilities of the AI Accelerator. It provides tools for data de-identification, collection, curation, and analysis, which can significantly enhance the speed and efficiency of research projects. The goal is to bridge clinical knowledge with engineering development for better outcomes in medical imaging.

This partnership aligns with Pro Medicus' broader AI strategy, which integrates AI solutions into its Visage 7 platform. The platform supports both proprietary and third-party AI algorithms, making it easier for clinicians to adopt AI-driven technologies.

The deal with UCSF underscores Pro Medicus' expanding role in the field of AI-driven medical imaging. As the company collaborates with one of the world’s leading academic medical centers, the potential for further advancements in AI technology appears promising, offering long-term growth for investors.